BACKGROUND AND AIMS: Hepatitis B viral markers and liver tests were used as predictors for development of hepatocellular carcinoma and progression to end-stage liver disease in 128 cirrhosis patients with hepatitis B. RESULTS: During a median follow-up of 63.5 months, 28 patients (21.9%) developed HCC and 36 (28.1%) died from non-HCC liver deaths. By multivariate analysis, independent predictors of HCC development and their hazard ratios were high alfa-fetoprotein (HR2.83, 95% CI 1.60-5.00, P = 0.0003), negative HBeAg (HR2.33, 95% CI 1.04-5.29, P = 0.04), and low alanine aminotransferase value (HR1.42, 95% CI 1.08-1.89, P = 0.02). Independent predictors of non-HCC liver deaths were HBeAg positivity (HR3.39, 95% CI 1.16-9.93, P = 0.02), decrease albumin (HR1.61, 95% CI 0.99-2.63, P = 0.05), decrease platelet count (HR2.54, 95% CI 1.03-6.25, P = 0.04), high ALT value (HR1.22, 95% CI 1.03-1.43, P = 0.02), and onset of encephalopathy (HR3.34, 95% CI 1.21-9.27, P = 0.02). CONCLUSIONS: HBeAg negativity, elevated AFP, and low ALT values predicted HCC development, while HBeAg positivity, abnormal liver tests, and low platelet counts identified patients with non-HCC liver deaths.
BACKGROUND AND AIMS: Hepatitis B viral markers and liver tests were used as predictors for development of hepatocellular carcinoma and progression to end-stage liver disease in 128 cirrhosispatients with hepatitis B. RESULTS: During a median follow-up of 63.5 months, 28 patients (21.9%) developed HCC and 36 (28.1%) died from non-HCC liver deaths. By multivariate analysis, independent predictors of HCC development and their hazard ratios were high alfa-fetoprotein (HR2.83, 95% CI 1.60-5.00, P = 0.0003), negative HBeAg (HR2.33, 95% CI 1.04-5.29, P = 0.04), and low alanine aminotransferase value (HR1.42, 95% CI 1.08-1.89, P = 0.02). Independent predictors of non-HCC liver deaths were HBeAg positivity (HR3.39, 95% CI 1.16-9.93, P = 0.02), decrease albumin (HR1.61, 95% CI 0.99-2.63, P = 0.05), decrease platelet count (HR2.54, 95% CI 1.03-6.25, P = 0.04), high ALT value (HR1.22, 95% CI 1.03-1.43, P = 0.02), and onset of encephalopathy (HR3.34, 95% CI 1.21-9.27, P = 0.02). CONCLUSIONS: HBeAg negativity, elevated AFP, and low ALT values predicted HCC development, while HBeAg positivity, abnormal liver tests, and low platelet counts identified patients with non-HCC liver deaths.
Authors: G Realdi; G Fattovich; S Hadziyannis; S W Schalm; P Almasio; J Sanchez-Tapias; E Christensen; G Giustina; F Noventa Journal: J Hepatol Date: 1994-10 Impact factor: 25.083
Authors: Peng Li; Shan-Shan Wang; Hui Liu; Ning Li; Michael A McNutt; Gang Li; Hui-Guo Ding Journal: World J Gastroenterol Date: 2011-11-07 Impact factor: 5.742
Authors: Melanie B Thomas; Deborah Jaffe; Michael M Choti; Jacques Belghiti; Steven Curley; Yuman Fong; Gregory Gores; Robert Kerlan; Phillipe Merle; Bert O'Neil; Ronnie Poon; Lawrence Schwartz; Joel Tepper; Francis Yao; Daniel Haller; Margaret Mooney; Alan Venook Journal: J Clin Oncol Date: 2010-08-02 Impact factor: 44.544
Authors: Robert D Mair; Antonia Valenzuela; Nghiem B Ha; Walid S Ayoub; Tami Daugherty; Glen A Lutchman; Gabriel Garcia; Aijaz Ahmed; Mindie H Nguyen Journal: Clin Gastroenterol Hepatol Date: 2012-08-16 Impact factor: 11.382
Authors: Myron John Tong; Leeyen Hsu; Carlos Hsien; Jia-Horng Kao; Francisco Antonio Durazo; Sammy Saab; Lawrence Mitchell Blatt Journal: Hepatol Int Date: 2010-04-07 Impact factor: 6.047
Authors: Myron John Tong; Thatcher Thi Huynh; Surachate Siripongsakun; Patrick Weijen Chang; Lori Terese Tong; Yen Phi Ha; Edward Alphonso Mena; Matthew Frank Weissman Journal: Hepatol Int Date: 2015-07-30 Impact factor: 6.047
Authors: Maja Thiele; Lise Lotte Gluud; Annette Dam Fialla; Emilie Kirstine Dahl; Aleksander Krag Journal: PLoS One Date: 2014-09-16 Impact factor: 3.240
Authors: Hephzibah Rani S Tagaram; Dhimant Desai; Guangfu Li; Dai Liu; C Bart Rountree; Kavitha Gowda; Arthur Berg; Shantu Amin; Kevin F Staveley-O'Carroll; Eric T Kimchi Journal: Pharmaceuticals (Basel) Date: 2016-03-24